AsymBio Launches End-to-End Tech Platforms for Biopharma Lifecycle
AsymBio, a subsidiary of Asymchem Group, has established integrated technology platforms including cell line development, upstream/downstream processing, conjugation toolbox, and analytics.
AsymBio, a subsidiary of Asymchem Group, announced that it has established integrated technology platforms spanning the full biopharmaceutical development lifecycle. Through its end-to-end service capabilities, the company provides streamlined, integrated workflows for client programs from early development to commercial manufacturing.
AsymBio is a technology-driven biopharmaceutical CDMO focused on accelerating innovation and providing integrated development and manufacturing services for clients. The integrated suite of technology platforms covers the entire biopharmaceutical development lifecycle, including the AmigoCHO Cell Line Development Platform for high-titer stable clones, Upstream and Downstream Process Development Platforms that accelerate timelines to as little as 9 weeks, a versatile Conjugation Toolbox, and specialized platforms for drug product, payload-linker CMC, and comprehensive analytics. These platforms enable rapid optimization, higher purity and yields, support for diverse bioconjugates like ADCs and emerging modalities, and full CMC services backing over 70 INDs and 13 NDAs.
AsymBio will continue to invest in R&D and technology development, with a focus on advanced technology platforms and data-enabled manufacturing processes. The company noted that technology underpins pharmaceutical innovation; by integrating advanced scientific approaches with large-scale manufacturing experience, AsymBio works to help address complex challenges in biopharmaceutical development, improve manufacturing efficiency and product quality, and support the reliable commercialization of innovative therapies for global clients.
